17.09.04 · mol-cell-bio / cellular-neuroscience

Ion channel pharmacology: channel types, blockers, and the molecular basis of excitability

stub3 tiersLean: nonepending prereqs

Anchor (Master): Hille, B. — Ion Channels of Excitable Membranes, 3rd ed. (2001)

Intuition Beginner

Ion channels are protein pores embedded in the cell membrane. Each channel has a water-filled hole through its centre that lets specific ions pass from one side of the membrane to the other. The channel is not always open — it has a gate that opens and closes in response to a signal. When the gate opens, millions of ions per second flow through.

Different channels respond to different signals. Voltage-gated channels open when the membrane voltage changes — these are the channels that produce action potentials. Ligand-gated channels open when a specific molecule (a neurotransmitter or drug) binds to them — these are the channels at synapses. Mechanosensitive channels open when the membrane is stretched.

The main channel families are organised by which ion they let through. Sodium channels ( $Na^{+}$ ) carry the upward stroke of the action potential. Potassium channels ( $K^{+}$ ) restore the resting voltage afterward. Calcium channels ( $Ca^{2 +}$ ) trigger neurotransmitter release and muscle contraction. Chloride channels ( $Cl^{-}$ ) stabilise the resting potential and dampen excitability.

Because each channel type has a unique molecular structure, drugs can be designed to block one type while leaving others alone. Tetrodotoxin (TTX), the poison from puffer fish, plugs sodium channels and prevents action potentials — which is why puffer fish must be prepared by licensed chefs. Local anaesthetics like lidocaine also block sodium channels, which is why a dental injection numbs pain without stopping your heart.

The pharmacology of ion channels is the basis of a large fraction of all prescription drugs: antiarrhythmics for the heart, anticonvulsants for epilepsy, antihypertensives for blood pressure, and sulfonylureas for diabetes all act by modifying specific ion channels.

Visual Beginner

The diagram shows four major ion channel families side by side, each drawn as a transmembrane protein with a central pore. Voltage-gated sodium channels are labelled with their blocker TTX at the extracellular mouth. Voltage-gated potassium channels are shown with TEA blocking the pore. Voltage-gated calcium channels have verapamil at the intracellular side. A ligand-gated channel (nAChR) is shown with its neurotransmitter binding site.

Below each channel, an arrow indicates the direction of ion flow when the channel is open, and a second arrow shows where the blocker physically occludes the pore.

Worked example Beginner

Consider what happens when a dentist injects lidocaine near a sensory nerve in your jaw.

Step 1. Lidocaine molecules diffuse through tissue and reach the membrane of the nerve axon. Being lipophilic, they partition into the lipid bilayer and reach the intracellular side of voltage-gated sodium channels.

Step 2. Lidocaine binds to a site inside the sodium channel pore, physically blocking sodium ions from passing through. The binding is stronger when the channel is open or inactivated — this is called use-dependent block.

Step 3. Because sodium channels in the injected region are blocked, action potentials arriving from the tooth cannot regenerate as they pass through the numbed stretch of axon. The signal dies out.

Step 4. The brain receives no signal from that region. No pain is perceived, even though the tooth is still being drilled. The effect wears off as lidocaine slowly unbinds and diffuses away.

This example illustrates the core principle of ion channel pharmacology: identify which channel type carries the signal you want to silence, find a molecule that blocks that channel, and deliver it to the right tissue. The reason lidocaine does not stop your heart is that cardiac sodium channels have a slightly different molecular structure — enough that lidocaine binds them less tightly at the doses used for local anaesthesia.

Check your understanding Beginner

Exercise (easy, multiple choice).

Tetrodotoxin (TTX) blocks voltage-gated sodium channels. If you apply TTX to a neuron, what happens when you try to stimulate it with a strong depolarising current?

A. The neuron fires an action potential with a lower peak voltage than normal. B. The neuron fires an action potential at a slower rate than normal. C. The neuron cannot fire an action potential at all because the sodium current that drives the upstroke is blocked. D. The neuron fires a normal action potential but the repolarisation is slower.

Hint

The upstroke of the action potential is driven by sodium influx through voltage-gated sodium channels. If those channels are blocked, what happens to the upstroke?

Answer

C. Without functional sodium channels, the regenerative positive feedback that drives the action potential upstroke cannot occur. No sodium influx means no depolarisation beyond whatever the stimulus current itself provides. The stimulus current decays with distance because the passive membrane acts as a low-pass filter. No spike propagates.

Exercise (medium, short answer).

Explain why local anaesthetics like lidocaine are more effective at blocking pain signals from actively firing neurons than from silent ones. What property of the drug-channel interaction accounts for this?

Hint

The term "use-dependent block" is relevant. Consider which conformational states of the sodium channel lidocaine binds most tightly to.

Answer

Lidocaine binds more tightly to the open and inactivated states of the sodium channel than to the resting (closed) state. Neurons that are actively firing action potentials cycle their sodium channels through the open and inactivated states repeatedly, giving lidocaine more opportunities to bind and block. Silent neurons keep their channels in the resting state, where lidocaine affinity is lower. This use-dependent selectivity is why lidocaine preferentially blocks pain fibres (which are firing rapidly in response to tissue damage) while sparing nearby neurons that happen to be quiet.

Formal definition Intermediate+

Ion channels are classified by their gating mechanism (what opens and closes them) and their selectivity (which ions they conduct). The major families are as follows.

Voltage-gated channels open in response to changes in membrane potential. They share a common architectural motif: four homologous domains (in sodium and calcium channels) or four separate subunits (in potassium channels), each containing six transmembrane helices (S1–S6). The S4 helix in each domain carries regularly spaced positively charged residues (arginine or lysine) and acts as the voltage sensor — when the membrane depolarises, the electric field pushes S4 outward, pulling the activation gate open. The pore loop between S5 and S6 forms the selectivity filter.

The three main voltage-gated families are:

Na $_{V}$ channels (Na $_{V}$ 1.1–1.9): conduct sodium, responsible for the action potential upstroke. Blocked by TTX (external site at the selectivity filter), saxitoxin, and local anaesthetics (internal site). Fast inactivation is mediated by the ball-and-chain mechanism: the intracellular loop between domains III and IV swings up and plugs the pore from the inside within milliseconds of opening.
K $_{V}$ channels (K $_{V}$ 1–12): conduct potassium, responsible for repolarisation and setting the resting potential. Blocked by tetraethylammonium (TEA, external pore block), 4-aminopyridine (internal block), and dendrotoxins (from mamba venom). Inactivation occurs via a ball-and-chain N-terminal mechanism (N-type inactivation, as in Shaker channels) or via constriction of the selectivity filter (C-type inactivation).
Ca $_{V}$ channels (Ca $_{V}$ 1–3): conduct calcium, trigger neurotransmitter release (Ca $_{V}$ 2.1 P/Q-type, Ca $_{V}$ 2.2 N-type), muscle contraction (Ca $_{V}$ 1.1 L-type), and cardiac pacemaking. Blocked by dihydropyridines (nifedipine, verapamil — L-type), $ω$ -conotoxins (N-type), and mibefradil (T-type).

Ligand-gated channels open when a specific molecule binds. The major classes include:

nAChR (nicotinic acetylcholine receptor): pentameric cation channel, depolarising, at the neuromuscular junction and in the brain. Blocked by curare, $α$ -bungarotoxin, and mecamylamine.
GABA $_{A}$ receptor: pentameric chloride channel, hyperpolarising (in most neurons), the primary inhibitory receptor in the brain. Potentiated by benzodiazepines, barbiturates, ethanol, and neurosteroids. Blocked by picrotoxin and bicuculline.
Glutamate receptors (AMPA, NMDA, kainate): cation channels, the primary excitatory receptors. NMDA receptors are additionally gated by a voltage-dependent magnesium block — they require both glutamate binding and depolarisation to open, making them coincidence detectors.

Inward-rectifier potassium channels (K $_{ir}$ ) conduct potassium more readily inward than outward. The K $_{ATP}$ subfamily (K $_{ir}$ 6.x + SUR regulatory subunit) closes when intracellular ATP is high and opens when ATP drops, coupling cellular metabolism to membrane excitability. Sulfonylureas (glibenclamide, tolbutamide) bind the SUR subunit and close K $_{ATP}$ channels, depolarising pancreatic beta cells and stimulating insulin release — the basis of a major class of oral antidiabetic drugs.

The selectivity filter

The selectivity filter is the narrowest region of the pore, typically 3–6 angstroms in diameter, lined with carbonyl oxygen atoms from the protein backbone. Potassium channels achieve >10,000-fold selectivity for $K^{+}$ over $Na^{+}$ through a mechanism identified by MacKinnon and co-workers (Nobel Prize 2003): the carbonyl oxygens in the selectivity filter are positioned at exactly the right spacing to coordinate a dehydrated $K^{+}$ ion (radius 1.33 A) but are too far apart to stabilise the smaller $Na^{+}$ (radius 0.95 A). Sodium channels achieve the reverse selectivity by a different arrangement of coordinating residues (the DEKA motif in the pore loops of the four domains).

Inactivation mechanisms

Voltage-gated channels do not stay open indefinitely after depolarisation. Fast (N-type) inactivation is the ball-and-chain mechanism: a tethered intracellular peptide blocks the pore from the cytoplasmic side. Slow (C-type) inactivation involves a constriction of the selectivity filter itself. Both mechanisms are voltage-dependent and contribute to the refractory period and to spike-frequency adaptation.

Pharmacological blockade and the Hill equation

The fraction of current remaining after applying a blocker at concentration $[B]$ is described by the Hill equation:

f_{unblocked} = \frac{1}{1 + ([ B ] / K _{d} ) ^{n_{H}}},

where $K_{d}$ is the dissociation constant (the concentration at which half the channels are blocked) and $n_{H}$ is the Hill coefficient (reflecting the number of binding sites and cooperativity). For TTX on Na $_{V}$ 1.4 (skeletal muscle), $K_{d} \approx 10$ nM and $n_{H} \approx 1$ ; for TEA on K $_{V}$ 1.1, $K_{d} \approx 0.2$ mM. The Hill equation is empirical — a full treatment requires the specific binding scheme and channel state model — but it provides a useful pharmacological summary.

Key mechanism Intermediate+

Mechanism: voltage-dependent gating of Na $_{V}$ channels.

The voltage sensor in each domain of the sodium channel is the S4 transmembrane helix, which carries 4–8 positively charged residues (arginines) at every third position along its length. At the resting potential ( $- 70$ mV), the intracellular negative potential pulls S4 inward, keeping the activation gate closed.

When the membrane depolarises, the electric field across the membrane weakens. The arginine charges on S4 are now driven outward by the reduced electrical force. S4 translates outward by roughly 4–15 angstroms and rotates, pulling on the S4–S5 linker. This linker is mechanically coupled to the S6 helix that forms the activation gate at the intracellular end of the pore. The S6 helices splay apart, opening the pore.

Each of the four domains moves with slightly different kinetics. Domain III and IV S4 segments move fastest and are responsible for activation. Domain IV S4 movement is also coupled to the fast inactivation gate (the IFM motif on the DIII–DIV linker). After the channel opens, the inactivation gate swings into position within 0.5–1 ms, plugging the pore from the inside.

The channel then resides in the inactivated state, which is distinct from the closed (resting) state. Recovery from inactivation requires repolarisation: the membrane must return to a negative potential so that S4 segments move back inward, which disengages the inactivation gate. This requirement underlies the refractory period — sodium channels cannot reopen until the membrane repolarises and the inactivation gate releases.

State diagram (three-state model):

Resting α_{m} β_{m} Open α_{h} β_{h} Inactivated

The Hodgkin-Huxley gating variables $m$ (activation) and $h$ (inactivation) are the probabilities of being in the activated and deinactivated states respectively, with the full open probability given by $m^{3} h$ (three independent activation gates, one inactivation gate). The voltage-dependent rate constants $α_{x} (V)$ and $β_{x} (V)$ were determined empirically by Hodgkin and Huxley from voltage-clamp experiments on the squid giant axon.

The pharmacological consequence is that different drugs stabilise different states. TTX binds in the outer mouth of the pore and prevents sodium permeation regardless of state (pore block). Local anaesthetics bind preferentially to the open and inactivated states (use-dependent block), which means they block firing neurons more effectively than resting ones. Antiarrhythmic drugs (Class I by the Vaughan-Williams classification) exploit this same state-dependent binding to suppress ectopic cardiac action potentials while sparing normal rhythm.

Advanced treatment Master

Channelopathies: ion channel diseases

Mutations in ion channel genes cause a growing family of diseases known as channelopathies. Because ion channels control the electrical behaviour of every excitable cell, mutations produce disorders of nerve, muscle, and heart.

Periodic paralyses (hyperkalaemic and hypokalaemic) are caused by mutations in skeletal muscle sodium (Na $_{V}$ 1.4, SCN4A gene) or potassium (K $_{V}$ 3.4) channels that impair inactivation or alter activation thresholds. The result is episodic muscle weakness or paralysis triggered by changes in serum potassium. Hyperkalaemic periodic paralysis (HyperPP) is caused by gain-of-function mutations in SCN4A that produce a persistent sodium current, chronically depolarising the muscle membrane until sodium channels enter a sustained inactivated state and the muscle becomes flaccid.

Long QT syndrome (LQTS) is caused by mutations in cardiac ion channels that prolong the ventricular action potential, visible on the ECG as a lengthened QT interval. LQT1 involves KCNQ1 (K $_{V}$ 7.1, the slow delayed rectifier); LQT2 involves KCNH2 (K $_{V}$ 11.1, the rapid delayed rectifier, hERG); LQT3 involves SCN5A (Na $_{V}$ 1.5, the cardiac sodium channel — a gain-of-function mutation impairing inactivation). The prolonged repolarisation predisposes to torsades de pointes and sudden cardiac death. Pharmacological management includes beta-blockers (LQT1), potassium supplementation, and mexiletine (a sodium channel blocker that shortens the action potential in LQT3).

Epilepsy is associated with mutations in neuronal sodium channels (SCN1A in Dravet syndrome, SCN2A and SCN8A in various epileptic encephalopathies), GABA $_{A}$ receptor subunits (GABRA1, GABRG2), and potassium channels (KCNQ2/3 in benign familial neonatal seizures). In Dravet syndrome, loss-of-function mutations in SCN1A preferentially affect inhibitory interneurons (which rely heavily on Na $_{V}$ 1.1), producing a net increase in network excitability — an illustration of why understanding which cell types express which channel isoforms matters for disease mechanism.

Episodic ataxia type 1 (EA1) is caused by mutations in KCNA1 (K $_{V}$ 1.1) that impair potassium channel function in cerebellar basket cells and motor neurons, producing attacks of uncoordinated movement and continuous muscle rippling (myokymia).

Cardiac channel pharmacology

The cardiac action potential differs markedly from the neuronal one: it lasts 200–400 ms (versus 1–2 ms) and has a pronounced plateau phase sustained by L-type calcium current (Ca $_{V}$ 1.2). Pharmacological modulation of cardiac channels is the basis of antiarrhythmic therapy, classified by the Vaughan-Williams scheme:

Class I: sodium channel blockers (lidocaine, mexiletine, flecainide). Subdivided by binding kinetics: Ia (intermediate — quinidine), Ib (fast — lidocaine), Ic (slow — flecainide).
Class II: beta-adrenergic receptor blockers (propranolol, metoprolol) — indirect channel modulation via reduced cAMP.
Class III: potassium channel blockers (amiodarone, sotalol, dofetilide) that prolong the action potential and refractory period by blocking hERG (K $_{V}$ 11.1).
Class IV: calcium channel blockers (verapamil, diltiazem) targeting L-type channels.

Amiodarone is the most broadly effective antiarrhythmic, blocking sodium, potassium, and calcium channels plus beta receptors. Its mechanism is nontrivial: it has a half-life of 40–55 days due to tissue accumulation, requires loading doses, and carries risks of pulmonary fibrosis, thyroid dysfunction (the molecule contains iodine), and hepatotoxicity. Sotalol blocks hERG potassium channels, prolonging repolarisation — but the same mechanism can paradoxically provoke torsades de pointes (proarrhythmia), illustrating the narrow therapeutic window of channel-blocking drugs.

The hERG channel (K $_{V}$ 11.1, KCNH2) is notorious in drug development because many compounds unintentionally block it, causing acquired long QT syndrome. Every new drug candidate is now screened for hERG blockade early in development (the "hERG assay"), making it one of the most consequential ion channels in pharmacology.

Patch-clamp technique and single-channel biophysics

The patch-clamp technique (Neher and Sakmann, Nobel Prize 1991) allows recording the current through a single ion channel. A glass micropipette with a tip diameter of about 1 $μ$ m is pressed against the cell membrane and gentle suction creates a high-resistance seal (gigaohm seal, $> 1 0^{9} Ω$ ). In cell-attached mode, the patch remains on the cell; in inside-out mode, the patch is excised with the cytoplasmic face exposed to the bath; in whole-cell mode, the patch is ruptured to record from the entire cell.

Single-channel recordings show discrete current steps: the channel is either open (conductance $γ$ ) or closed (zero conductance). For a typical voltage-gated sodium channel, $γ \approx 10$ – $20$ pS (picosiemens). At a driving force of 100 mV, a single channel carries about 1–2 pA — roughly $6 \times 1 0^{6}$ ions per second. The stochastic opening and closing follows Markov kinetics; dwell times in the open state are exponentially distributed.

The macroscopic current recorded in whole-cell mode is the sum of thousands of single-channel currents. The Hodgkin-Huxley conductance $g_{X} (V, t) = N \cdot P_{open} (V, t) \cdot γ$ , where $N$ is the number of channels, $P_{open}$ is the open probability (itself a function of the gating variables), and $γ$ is the single-channel conductance. The deterministic HH equations are the large- $N$ limit of this stochastic process.

Channel structure: cryo-EM insights

Cryo-electron microscopy has resolved the atomic structure of several ion channels:

Na $_{V}$ 1.7 (Shen et al., Science 2019; Pan et al., Science 2019): the structure revealed the voltage-sensor domains, the pore module, the fast-inactivation gate (the IFM motif lodging in a hydrophobic pocket), and the binding site for the pore blocker saxitoxin. Na $_{V}$ 1.7 is a target for novel non-opioid analgesics because it mediates pain signalling in dorsal root ganglion neurons.
K $_{V}$ 1.2/K $_{V}$ 2.1 chimera (Long et al., Science 2005, 2007): showed the S4–S5 linker acting as a mechanical lever, coupling voltage-sensor movement to gate opening. The pore domain is structurally homologous to bacterial KcsA.
KcsA (Doyle et al., Science 1998): the first potassium channel structure, revealing the selectivity filter with two $K^{+}$ ions queued in single file, separated by a water molecule — the "knock-on" mechanism for high-throughput conduction with high selectivity.

Toxin pharmacology

Biological toxins have been indispensable tools for identifying and characterising ion channels because of their high potency and specificity:

Tetrodotoxin (TTX): from puffer fish, newts, and certain octopi. Blocks Na $_{V}$ channels by binding at the extracellular mouth of the selectivity filter (site 1). $K_{d}$ varies across isoforms: Na $_{V}$ 1.4 (skeletal muscle) and Na $_{V}$ 1.7 are TTX-sensitive ( $K_{d} \approx 10$ nM); Na $_{V}$ 1.5 (cardiac) and Na $_{V}$ 1.8 (DRG) are TTX-resistant ( $K_{d} > 1 μ$ M).
$ω$ -Conotoxins: from cone snail venom. Block specific Ca $_{V}$ channel subtypes: GVIA blocks N-type (Ca $_{V}$ 2.2), MVIIA (ziconotide, FDA-approved for intractable pain) blocks N-type intrathecally.
Scorpion toxins: $α$ -toxins (from Androctonus, Leiurus) bind to Na $_{V}$ site 3 and slow inactivation, causing prolonged sodium influx and repetitive firing. $β$ -toxins bind to site 4 and shift activation to more negative potentials.
Dendrotoxins: from mamba venom. Block K $_{V}$ 1.1, K $_{V}$ 1.2, and K $_{V}$ 1.6 channels, prolonging action potentials and enhancing neurotransmitter release.
$α$ -Bungarotoxin: from banded krait venom. Irreversibly blocks nAChR at the neuromuscular junction, causing flaccid paralysis.

TRP channels and CFTR

TRP channels (Transient Receptor Potential) are a large superfamily of nonselective cation channels that respond to temperature, chemical ligands, and mechanical stimuli. TRPV1 is activated by capsaicin (chilli peppers), heat (>43 $^{\circ}$ C), and protons; TRPM8 by menthol and cold (<25 $^{\circ}$ C); TRPA1 by mustard oil and environmental irritants. They are important drug targets for chronic pain.

CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) is an atypical ABC transporter that evolved into a chloride channel. It is gated by ATP binding and hydrolysis at its nucleotide-binding domains, not by voltage. The most common cystic fibrosis mutation ( $Δ$ F508) causes protein misfolding and degradation before it reaches the membrane. The drug ivacaftor (a CFTR potentiator) and lumacaftor (a corrector that aids folding) target CFTR directly and have transformed treatment for a subset of cystic fibrosis patients.

Optogenetics: channelrhodopsin

Channelrhodopsin-2 (ChR2), from the alga Chlamydomonas reinhardtii, is a light-gated cation channel that opens in response to blue light (~470 nm). When expressed in neurons via viral gene delivery, ChR2 allows precise optical control of spiking: a pulse of blue light opens the channel, sodium and other cations flow in, and the neuron depolarises and fires. Combined with halorhodopsin (a light-gated chloride pump for silencing), optogenetics has become a standard tool for causal circuit analysis in neuroscience.

The optogenetic principle — expressing an exogenous ion channel in a defined cell population and controlling it with an external signal — generalises beyond light. Chemogenetics (DREADDs: Designer Receptors Exclusively Activated by Designer Drugs) uses engineered G-protein-coupled receptors activated by an inert small molecule (clozapine-N-oxide), providing longer-timescale, less invasive control than light.

Exercises Intermediate+

Exercise 2 (easy, short answer).

Explain the concept of "use-dependent block" in the context of local anaesthetics and sodium channels.

Hint

Consider the three states of the sodium channel (resting, open, inactivated) and which state the drug binds most tightly to.

Answer

Use-dependent block means the drug blocks more effectively at higher firing rates. Local anaesthetics bind to the open and inactivated states of the sodium channel with higher affinity than to the resting state. At rest, most channels are in the resting state and the drug binds weakly. During repetitive firing, channels cycle through open and inactivated states, exposing more high-affinity binding sites. The block accumulates with each action potential, making the drug more effective against rapidly firing neurons (such as pain fibres) than against slowly firing or silent ones.

Exercise 4 (medium, short answer).

Sulfonylureas (e.g., glibenclamide) are oral antidiabetic drugs that close K $_{ATP}$ channels in pancreatic beta cells. Explain the chain of events from K $_{ATP}$ closure to insulin release.

Hint

K $_{ATP}$ channels set the resting potential of the beta cell. Closing them changes the membrane voltage, which affects voltage-gated calcium channels.

Answer

In the resting beta cell, K $_{ATP}$ channels are open (because ATP levels are moderate), holding the membrane potential near the potassium equilibrium potential (about $- 70$ mV). Sulfonylureas bind the SUR subunit and close K $_{ATP}$ channels. Potassium conductance drops, the membrane depolarises (because the residual conductances pull the voltage away from $E_{K}$ ), and voltage-gated calcium channels open. Calcium influx raises intracellular $[Ca^{2 +}]$ , which triggers exocytosis of insulin-containing vesicles. The result is insulin release independent of glucose level — which is why sulfonylureas can cause hypoglycaemia.

Exercise 5 (medium, multiple choice).

In Dravet syndrome, loss-of-function mutations in SCN1A (Na $_{V}$ 1.1) cause severe epilepsy. Paradoxically, a sodium channel loss-of-function leads to increased network excitability. Why?

A. Na $_{V}$ 1.1 is expressed primarily in excitatory pyramidal neurons; losing it reduces inhibition. B. Na $_{V}$ 1.1 is expressed preferentially in inhibitory interneurons; losing it reduces inhibitory output, producing net disinhibition. C. The mutation causes a compensatory upregulation of all sodium channel isoforms, producing hyperexcitability. D. Na $_{V}$ 1.1 is a potassium channel; the mutation reduces potassium conductance.

Hint

Which cell type depends most heavily on Na $_{V}$ 1.1 for action potential generation? What happens when that cell type cannot fire?

Answer

B. Na $_{V}$ 1.1 is the dominant sodium channel isoform in many GABAergic interneurons. These inhibitory cells have small cell bodies and rely on Na $_{V}$ 1.1 for reliable action potential initiation. Loss of function reduces the firing of inhibitory interneurons, which reduces inhibitory synaptic output onto excitatory pyramidal cells. The result is net disinhibition — the excitatory network becomes hyperexcitable because the brake is released. This is a nontrivial example of why cell-type-specific expression patterns matter for understanding disease mechanism.

Exercise 6 (hard, short answer).

The hERG channel (K $_{V}$ 11.1) is blocked by a large number of chemically unrelated drugs, causing acquired long QT syndrome. What structural feature of the hERG channel makes it unusually susceptible to promiscuous drug block?

Hint

Compare the inner vestibule of hERG to that of other potassium channels. The relevant structural features are the S6 helices and the aromatic residues lining the pore.

Answer

The hERG channel has an unusually large inner vestibule compared to other K $_{V}$ channels, with two key aromatic residues (Phe656 and Tyr652 on the S6 helix) that provide hydrophobic and $π$ -stacking interactions with a wide range of drug molecules. Most other potassium channels have smaller inner vestibules with polar or charged residues that are more selective. The spacious, hydrophobic binding pocket of hERG accommodates many structurally diverse drugs, which is why hERG blockade is the single most common cause of drug-induced cardiac arrhythmia and why every new drug candidate is now routinely screened against hERG.

Exercise 7 (hard, symbolic).

A voltage-gated sodium channel is modelled by a three-state Markov chain: Resting $\leftrightarrow$ Open $\leftrightarrow$ Inactivated. Write the master equation for the probabilities $P_{R}$ , $P_{O}$ , $P_{I}$ (with $P_{R} + P_{O} + P_{I} = 1$ ). Under voltage clamp at fixed $V$ , derive the steady-state open probability $P_{O}^{(\infty)}$ in terms of the rate constants.

Hint

At steady state, detailed balance gives $P_{R} α = P_{O} β$ and $P_{O} γ = P_{I} δ$ , where $α, β$ are the R↔O rates and $γ, δ$ are the O↔I rates. Use the normalisation constraint.

Answer

The master equations are:

\frac{d P _{R}}{d t} = - α P_{R} + β P_{O}, \frac{d P _{O}}{d t} = α P_{R} - β P_{O} - γ P_{O} + δ P_{I}, \frac{d P _{I}}{d t} = γ P_{O} - δ P_{I} .

At steady state ( $d P / d t = 0$ ), detailed balance gives $P_{R} = (β / α) P_{O}$ and $P_{I} = (γ / δ) P_{O}$ . Substituting into the normalisation constraint:

P_{O} (\frac{β}{α} + 1 + \frac{γ}{δ}) = 1, so P_{O}^{(\infty)} = \frac{1}{1 + β / α + γ / δ} = \frac{α δ}{α δ + β δ + α γ} .

The Hodgkin-Huxley approximation sets $P_{O} = m^{3} h$ with $m$ governed by $α_{m}, β_{m}$ and $h$ governed by $α_{h}, β_{h}$ , which is a factored form of this three-state model. The full Markov model is more flexible because it allows state-dependent binding of drugs (a blocker that binds only to the open state has a blocking rate proportional to $P_{O}$ , not to $P_{R} + P_{O} + P_{I}$ ).

Connections Master

Ion channel pharmacology sits at the intersection of membrane biophysics, molecular biology, and clinical medicine. The connections radiate in several directions.

To structural biology and drug design. Cryo-EM structures of Na $_{V}$ 1.7 (pain signalling), Na $_{V}$ 1.5 (cardiac), and hERG have opened rational drug design campaigns. The Na $_{V}$ 1.7-specific blockers under development aim to provide analgesia without the systemic sodium channel blockade that limits current local anaesthetics. The challenge is isoform selectivity: nine Na $_{V}$ subtypes share a common pore architecture, and achieving subtype-specific blockade requires exploiting subtle structural differences in the voltage-sensor domains or the intracellular gates.

To systems neuroscience. The diversity of ion channel expression across cell types determines the computational properties of neural circuits. Fast-spiking parvalbumin interneurons express high levels of K $_{V}$ 3.1, enabling sustained high-frequency firing. Low-threshold spiking somatostatin interneurons express K $_{V}$ 3.2 and T-type calcium channels, producing bursting behaviour. The pharmacological manipulation of specific cell types via their unique channel complements is an emerging strategy in circuit neuroscience.

To cardiac electrophysiology and drug safety. The hERG liability problem has reshaped pharmaceutical development. The ICH S7B guideline mandates hERG testing for all new drugs. Automated patch-clamp platforms (QPatch, PatchXpress, SyncroPatch) now screen thousands of compounds per week against hERG. The broader lesson is that ion channel pharmacology is not merely a therapeutic strategy but also a safety concern: any drug that inadvertently modifies channel function can produce life-threatening arrhythmias or seizures.

To genetics and precision medicine. Channelopathies are among the most genetically tractable neurological disorders. Whole-exome sequencing now identifies SCN1A mutations in Dravet syndrome patients within weeks of diagnosis, guiding treatment (sodium channel blockers like carbamazepine are contraindicated because they further impair interneuron function; stiripentol and fenfluramine are preferred). The precision-medicine paradigm — sequence, identify the mutation, choose the drug that compensates for the specific biophysical defect — is most advanced in the channelopathy field.

To evolutionary biology. Ion channels are ancient — voltage-gated potassium channels exist in bacteria (KcsA), and the four-domain architecture of sodium channels likely arose from two rounds of gene duplication from a single-domain potassium channel ancestor. The conservation of the selectivity filter motif across all domains of life makes ion channels one of the best examples of molecular evolution preserving a core mechanistic solution across billions of years.

Historical notes Master

The history of ion channel pharmacology is inseparable from the history of neurophysiology itself.

1791. Luigi Galvani demonstrates that electrical stimulation causes muscle contraction in frog legs, establishing the electrical basis of nerve function.

1902. Julius Bernstein proposes the "membrane theory": the resting potential is a diffusion potential set by potassium permeability. He hypothesised that excitation involves a transient loss of selective permeability, allowing all ions to pass — a view that lasted fifty years until Hodgkin and Huxley showed that excitation involves a specific increase in sodium permeability followed by a specific increase in potassium permeability.

1949. Hodgkin and Katz show that reducing external sodium concentration diminishes the action potential overshoot, demonstrating that sodium influx drives the upstroke. This was the first experimental proof that the spike is not a general membrane breakdown but a selective sodium event.

1952. Hodgkin and Huxley publish their four papers in the Journal of Physiology, culminating in the quantitative model. They used the voltage-clamp technique (developed by Cole and Marmont) to hold the squid giant axon at controlled voltages and measure the resulting ionic currents. By pharmacologically separating sodium and potassium currents (using sodium substitution and early potassium blockers), they isolated each current, fitted the gating kinetics, and reconstructed the action potential mathematically. The model predicted the spike shape and conduction velocity with remarkable accuracy. Nobel Prize in Physiology or Medicine, 1963 (shared with Eccles).

1964. Nakamura, Nakajima, and Grundfest apply TTX to the squid axon and show selective abolition of the sodium current. The same year, Armstrong and Binstock use TEA to selectively block potassium current. These two toxins become the standard tools for dissecting ionic currents and are used in virtually every voltage-clamp study for the next three decades.

1970. Armstrong and Bezanilla measure "gating current" — the tiny displacement current produced by the movement of the voltage-sensor charges (the S4 arginines) — proving that voltage-dependent gating involves the physical movement of charged particles within the membrane. This was the first biophysical evidence for what would later be confirmed structurally as the S4 helix.

1976. Neher and Sakmann record single-channel currents from frog muscle using the patch-clamp technique, demonstrating that ion channels open and close in discrete stochastic steps. Nobel Prize, 1991.

1982. Numa and colleagues clone the nicotinic acetylcholine receptor subunits, providing the first primary sequence of an ion channel. The era of molecular channel biology begins.

1998. Roderick MacKinnon's group solves the crystal structure of KcsA, the bacterial potassium channel, revealing the selectivity filter mechanism. This is the first atomic-resolution structure of any ion channel. Nobel Prize in Chemistry, 2003.

2003–2005. The MacKinnon group solves the structure of a mammalian K $_{V}$ channel (K $_{V}$ 1.2), showing the S4–S5 linker coupling the voltage sensor to the pore gate.

2017–2019. Cryo-EM structures of full-length mammalian Na $_{V}$ channels (Na $_{V}$ 1.4, Na $_{V}$ 1.7) are solved, revealing the architecture of the voltage-sensor domains, the pore, the fast-inactivation gate, and drug-binding sites.

2020s. Na $_{V}$ 1.7-selective blockers enter clinical trials for chronic pain. The promise is a non-opioid analgesic that targets the peripheral pain-signalling sodium channel without affecting cardiac or brain sodium channels. As of this writing, several candidates have reached Phase II/III trials but none has yet achieved FDA approval, illustrating the difficulty of achieving sufficient isoform selectivity in practice.

Bibliography Master

Hodgkin, A. L. & Huxley, A. F. — A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol. 117 (1952) 500–544.
Hille, B. — Ion Channels of Excitable Membranes, 3rd ed. Sinauer Associates, 2001.
Alberts et al. — Molecular Biology of the Cell, 7th ed. Garland Science, 2022. Ch. 11.
Lodish et al. — Molecular Cell Biology, 9th ed. W. H. Freeman, 2021. Ch. 22.
Doyle, D. A. et al. — The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 280 (1998) 69–77.
Long, S. B., Campbell, E. B. & MacKinnon, R. — Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 309 (2005) 897–903.
Pan, X. et al. — Structure of the human voltage-gated sodium channel Nav1.4 in complex with beta1. Science 362 (2018) eaau2484.
Shen, H. et al. — Structures of human Nav1.7 channel in complex with both auxiliary beta1 and beta2 subunits. Science 363 (2019) 1303–1308.
Neher, E. & Sakmann, B. — Single-channel currents recorded from membrane of denervated frog muscle fibres. Nature 260 (1976) 799–802.
Catterall, W. A. — From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26 (2000) 13–25.
Sanguinetti, M. C. & Tristani-Firouzi, M. — hERG potassium channels and cardiac arrhythmia. Nature 440 (2006) 463–469.
Waxman, S. G. — Channelopathies in genetic epilepsy: how mutations in sodium channels cause disease. Nature Rev. Neurol. 10 (2014) 117–125.
MacKinnon, R. — Nobel Lecture: Potassium channels and the atomic basis of selective ion conduction. Biosci. Rep. 24 (2004) 75–100.
Caterina, M. J. et al. — The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816–824.
Deisseroth, K. — Optogenetics: controlling the brain with light. Scientific American 303 (2010) 48–55.

Prerequisites

17.09.01 pending
17.09.02 pending

Tier anchors

beginner: Alberts et al., Molecular Biology of the Cell, 7th ed. (2022), Ch. 11
intermediate: Lodish et al., Molecular Cell Biology, 9th ed. (2021), Ch. 22
master: Hille, B. — Ion Channels of Excitable Membranes, 3rd ed. (2001)

References

Alberts et al. — Molecular Biology of the Cell, 7th ed. (Garland Science, 2022) · Ch. 11 Ion Channels and the Electrical Properties of Membranes
Lodish et al. — Molecular Cell Biology, 9th ed. (W. H. Freeman, 2021) · Ch. 22 Nerve Cells
Hille, B. — Ion Channels of Excitable Membranes, 3rd ed. (Sinauer, 2001) · Ch. 1-6 Channel structure, gating, pharmacology
Hodgkin, A. L. & Huxley, A. F. — A quantitative description of membrane current · J. Physiol. 117 (1952) 500-544

Estimated time

beginner: 15m
intermediate: 30m
master: 45m